151 related articles for article (PubMed ID: 7078263)
21. Clinical and laboratory manifestations of congenital dyserythropoietic anemia type I in young adults.
Shalev H; Kapleushnik Y; Haeskelzon L; Degani O; Kransnov T; Sphilberg O; Moser A; Yaniv I; Tamary H
Eur J Haematol; 2002 Mar; 68(3):170-4. PubMed ID: 12068798
[TBL] [Abstract][Full Text] [Related]
22. [Iron-overload in patients on maintenance hemodialysis: diagnostic criteria, indications and treatment by desferrioxamine (author's transl)].
Simon P; Bonn F; Guezennec M; Tanquerel T; Ksang
Nephrologie; 1981; 2(4):165-70. PubMed ID: 7329501
[TBL] [Abstract][Full Text] [Related]
23. Normal serum ferritin levels in a patient with HEMPAS syndrome and iron overload.
Faruqui S; Abraham A; Berenfeld MR; Gabuzda TG
Am J Clin Pathol; 1982 Jul; 78(1):97-101. PubMed ID: 7102612
[TBL] [Abstract][Full Text] [Related]
24. A congenital dyserythropoietic anaemia variant presenting as hydrops fetalis.
Carter C; Darbyshire PJ; Wickramasinghe SN
Br J Haematol; 1989 Jun; 72(2):289-90. PubMed ID: 2757972
[No Abstract] [Full Text] [Related]
25. Continuous intravenous deferoxamine infusion. Treatment of secondary hemochromatosis in adults.
Blume KG; Beutler E; Chillar RK; Fahey JL; Sharkoff D; Zia PK
JAMA; 1978 May; 239(20):2149-51. PubMed ID: 642157
[TBL] [Abstract][Full Text] [Related]
26. Variant of congenital dyserythropoietic anemia.
Hanna WT; Machado EA; Montgomery RN; Lange RD
South Med J; 1985 May; 78(5):616-8. PubMed ID: 3992310
[TBL] [Abstract][Full Text] [Related]
27. Congenital dyserythropoietic anaemia type II associated with a new type of G6PD deficiency (G6PD Gabrovizza).
Ventura A; Panizon F; Soranzo MR; Veneziano G; Sansone G; Testa U; Luzzatto L
Acta Haematol; 1984; 71(4):227-34. PubMed ID: 6426235
[TBL] [Abstract][Full Text] [Related]
28. Advances in the use of iron-chelating agents for the treatment of iron overload.
Modell B
Prog Hematol; 1979; 11():267-312. PubMed ID: 392593
[No Abstract] [Full Text] [Related]
29. [A case of idiopathic hemochromatosis associated with gastric cancer].
Sugie Y; Tsuji H; Nomiyama K; Ishitsuka T; Akagi K; Fujishima M; Shibuya T; Okamura T
Fukuoka Igaku Zasshi; 1992 Sep; 83(9):357-61. PubMed ID: 1427560
[TBL] [Abstract][Full Text] [Related]
30. Iron loading anaemias.
Mehta BC; Pandya BG; Mehta JB; Bisariya BN
J Assoc Physicians India; 1989 Dec; 37(12):754-6. PubMed ID: 2636578
[TBL] [Abstract][Full Text] [Related]
31. [Post-transfusion hemochromatosis. Results of a study carried out in Blood Transfusion Centers. Analysis of 15 cases treated with subcutaneous perfusion of Desferal. Working group "Transfusion Techniques and Therapeutics"].
Jaulmes D; Quarre MC; Audat F; Gaonach MJ
Transfus Clin Biol; 1994; 1(1):55-64. PubMed ID: 8186855
[TBL] [Abstract][Full Text] [Related]
32. Ferritin in the red cells of normal subjects and patients with iron deficiency and iron overload.
Cazzola M; Arosio P; Barosi G; Bergamaschi G; Dezza L; Ascari E
Br J Haematol; 1983 Apr; 53(4):659-65. PubMed ID: 6830706
[TBL] [Abstract][Full Text] [Related]
33. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
Lombardo T; Ferro G; Frontini V; Percolla S
Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
[TBL] [Abstract][Full Text] [Related]
34. Congenital dyserythropoietic anaemia.
Prasher N; Prasher BS
J Assoc Physicians India; 1989 Jul; 37(7):467-8. PubMed ID: 2613664
[TBL] [Abstract][Full Text] [Related]
35. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function.
Marciani MG; Cianciulli P; Stefani N; Stefanini F; Peroni L; Sabbadini M; Maschio M; Trua G; Papa G
Haematologica; 1991; 76(2):131-4. PubMed ID: 1937171
[TBL] [Abstract][Full Text] [Related]
36. Proton pump inhibitors use suppresses iron absorption in congenital dyserythropoietic anemia.
Shalev H; Quider AA; Harosh MB; Kapelushnik J
Pediatr Hematol Oncol; 2016; 33(7-8):457-461. PubMed ID: 27960647
[TBL] [Abstract][Full Text] [Related]
37. Congenital dyserythropoietic anemia type II: epidemiology, clinical appearance, and prognosis based on long-term observation.
Heimpel H; Anselstetter V; Chrobak L; Denecke J; Einsiedler B; Gallmeier K; Griesshammer A; Marquardt T; Janka-Schaub G; Kron M; Kohne E
Blood; 2003 Dec; 102(13):4576-81. PubMed ID: 12933587
[TBL] [Abstract][Full Text] [Related]
38. Oral iron chelator deferasirox in the treatment of secondary hemochromatosis following bone marrow transplantation in a patient with severe aplastic anemia.
Quarta A; Melpignano A; Quarta G
Acta Haematol; 2011; 125(4):219-21. PubMed ID: 21266801
[TBL] [Abstract][Full Text] [Related]
39. [Ocular side effects of deferoxamine therapy in aplastic anemia with transfusion-induced hemochromatosis].
Spraul CW; Schicketanz C; Lang GE
Klin Monbl Augenheilkd; 1996 Jul; 209(1):31-6. PubMed ID: 8965474
[TBL] [Abstract][Full Text] [Related]
40. Congenital diserythropoietic anemia type I. Report on monozygotic twins with associated hemochromatosis and short stature.
Facon T; Mannessier L; Lepelley P; Weill J; Fenaux P; Dupriez B; Morel P; Jouet JP
Blut; 1990 Oct; 61(4):248-50. PubMed ID: 2224147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
